Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for pleural mesothelioma in situ has been reported in the published literature.
No clinical trials have been registered for pleural mesothelioma in situ.
15 publications have been identified in PubMed for pleural mesothelioma in situ. Research spans Diagnostic / Biomarker (53%), Review / Meta-Analysis (20%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 8 | 53% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:48 AM UTC
European rare disease database
Research summaries
3 |
20% |
Patient case studies | 2 | 13% |
Laboratory research | 2 | 13% |
Findley J (2026). [PMID: 41721215](https://pubmed.ncbi.nlm.nih.gov/41721215/). *Cytopathology : official journal of the British Society for Clinical Cytology*. [Diagnostic / Biomarker]
Şeker NS (2026). [PMID: 41212604](https://pubmed.ncbi.nlm.nih.gov/41212604/). *Cytopathology : official journal of the British Society for Clinical Cytology*. [Diagnostic / Biomarker]
Zhu L (2025). [PMID: 40412248](https://pubmed.ncbi.nlm.nih.gov/40412248/). *Ecotoxicology and environmental safety*. [Diagnostic / Biomarker]
Lucà S (2025). [PMID: 39941848](https://pubmed.ncbi.nlm.nih.gov/39941848/). *Cancers*. [Basic Science / Preclinical]
Ye H (2025). [PMID: 40017520](https://pubmed.ncbi.nlm.nih.gov/40017520/). *Frontiers in cardiovascular medicine*. [Diagnostic / Biomarker]
Quaranta A (2025). [PMID: 40566743](https://pubmed.ncbi.nlm.nih.gov/40566743/). *Histopathology*. [Case Report / Case Series]
Danuzzo F (2024). [PMID: 38547377](https://pubmed.ncbi.nlm.nih.gov/38547377/). *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. [Diagnostic / Biomarker]
Jones TE (2024). [PMID: 38514361](https://pubmed.ncbi.nlm.nih.gov/38514361/). *Journal of the American Society of Cytopathology*. [Diagnostic / Biomarker]
Hassan A (2024). [PMID: 38789301](https://pubmed.ncbi.nlm.nih.gov/38789301/). *Pathology*. [Diagnostic / Biomarker]
Sonobe H (2024). [PMID: 39006698](https://pubmed.ncbi.nlm.nih.gov/39006698/). *Cureus*. [Basic Science / Preclinical]
AI-curated news mentioning pleural mesothelioma in situ
Updated May 21, 2026
A case report details the first instance of pleural mesothelioma treated with cytoreductive surgery and hyperthermic intrathoracic chemotherapy in Kazakhstan. This innovative approach may provide insights into new treatment strategies for this rare cancer.
A meta-analysis evaluates the impact of cytoreductive surgery with or without hyperthermic intrathoracic chemotherapy (HITHOC) on survival and perioperative outcomes in pleural mesothelioma. The findings contribute to understanding treatment efficacy in this challenging disease.
New research focuses on optimizing immunotherapy responses in pleural mesothelioma, presenting clinical data and alternative evaluation models. This study aims to enhance treatment strategies for this challenging cancer.